Human/Primate CXCL1/GRO alpha/KC/CINC-1 Alexa Fluor® 350-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: CXCL1/GRO alpha/KC/CINC-1

The gene for CXCL1/GRO alpha was initially discovered in hamster cells, using subtractive hybridization techniques, as a message that is over-expressed in tumorigenic cells and in normal cells during growth stimulation. The hamster cDNA was cloned and used as a probe for the subsequent cloning of the human GRO cDNA. Independently, a cDNA encoding a secreted protein with melanoma growth stimulating activity (MGSA) was also cloned from a human melanoma cell line and found to be identical to GRO. In addition to the initially cloned GRO gene, now designated CXCL1, two additional GRO genes, GRO beta or MIP-2 alpha and GRO gamma or MIP‑2 beta, which shared 90% and 86% amino acid sequence homology, respectively, with CXCL1, have been identified. All three human GROs are members of the alpha (C-X-C) subfamily of chemokines.

The three GRO cDNAs encode 107 amino acid precursor proteins from which the N-terminal 34 amino acid residues are cleaved to generate the mature GROs. There are no potential N-linked glycosylation sites in the amino acid sequences. GRO expression is inducible by serum or PDGF and/or by a variety of inflammatory mediators, such as IL-1 and TNF, in monocytes, fibroblasts, melanocytes, and epithelial cells. In certain tumor cell lines, GRO is expressed constitutively.

Similar to other alpha chemokines, the three GRO proteins are potent neutrophil attractants and activators. In addition, these chemokines are also active toward basophils. All three GROs can bind with high affinity to the IL-8 receptor type B. It remains to be seen if a unique GRO receptor(s) also exist. The rat homolog of human CXCL1, CINC, is much more active than human CXCL1 on rat neutrophils, suggesting that this cytokine may have selective species specificity.

Product Datasheets

Product Specific Notices

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

Related Research Areas

• Alpha Granule Soluble Molecules
• Chemokines and Receptors in Allergy and Asthma
• Chemokines and Receptors in Angiogenesis
• CXC Chemokines and Receptors
• Inflammatory Mediators
• Macrophage Activation Markers
• Microglia Activation Markers
• Neuroinflammatory Factors